Roles
- Professor of Clinical Medicine
-
Biography
Dr. Levy is a Professor of Medicine in the Division of Digestive Health and Liver Diseases and is the Associate Director of the Schiff Center for Liver Diseases at the University of Miami. She was awarded the Arthur Hertz Endowed Chair in Liver Diseases.
Dr. Levy’s clinical research program focuses on autoimmune and cholestatic liver diseases, and in the study of porphyrias. She is particularly interested in clinical trial development and conduct. Dr. Levy is a member of the steering committees for the International Primary Sclerosing Cholangitis Study group (IPSCSG), the Global PBC study group and the Cholestatic and Autoimmune Liver Diseases SIG in AASLD and serves as an advisor for several patient support groups and foundations. She is currently the chair elect for the AASLD Practice Guidelines Committee. Dr Levy’s expertise is recognized internationally.
Dr. Levy received her M.D. from Universidade Federal do Rio de Janeiro (UFRJ). She completed house staff training both at her home University and subsequently at University of Miami/Jackson Memorial Hospital, in Miami, FL. Dr. Levy completed her 3-year Gastroenterology Fellowship at Mayo Clinic in Rochester, Minnesota, and a 1-year Transplant Hepatology Fellowship at University of Florida, in Gainesville, FL. -
Education & Training
Education
Post Graduate Training
Licensures and Certifications
-
Honors & Awards
-
Research Interests
Dr. Levy is research focuses on cholestatic and autoimmune liver diseases, with an emphasis on clinical trial development and conduct. -
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Articles & News
Collaboration Over Ego: How Dr. Cynthia Levy’s Global Leadership Earned a Prestigious Hepatology Honor
Miller School Hosts Miami Gastroenterology Congress
Miller School of Medicine Named Wilson Disease Association Center of Excellence
Disclaimer:
Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 38 clinical trials.
-
A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Seamless, Adaptive, Safety, Dose-Finding, and Phase 3 Clinical Study of UX701 AAV-Mediated Gene Transfer for the Treatment of Wilson Disease
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 1/Phase 2
- Enrollment Status: Closed
-
This is a phase III, randomised, double-blind, multicentre, event-driven, parallel group study to evaluate the efficacy and safety of elafibranor 120 mg film-coated tablet once daily comparedwith placebo in male and female participants aged 18 to 75 years inclusive with PSC.
- Principal Investigator: Cynthia Levy
- Study Phase: TBD
- Enrollment Status: Open
-
This is an Expanded Access Program (EAP) conducted under the existing IND for bitopertin (DISC-1459). The program is intended to provide access to bitopertin for patients with EPP or XLP who lack satisfactory therapeutic alternatives in the US.
- Principal Investigator: Cynthia Levy
- Study Phase: TBD
- Enrollment Status: Open
-
56yearold White Hispanic woman with cirrhoticstage PBC and incomplete response to UDCA. Her history includes covert hepatic encephalopathy and small, nonbleeding esophageal varices, without ascites or variceal bleeding. Her MELD is 11, limiting transplant eligibility. She has severe, refractory pruritus unresponsive to cholestyramine, antihistamines, and naltrexone. She previously participated in a linerixibat trial with complete resolution of itching and marked improvement in quality of life, but was withdrawn due to gradual bilirubin increase (1.5 → 2.5 mg/dL over several years). A trial of seladelpar was also ineffective and discontinued due to bilirubin rise. She has been off linerixibat since October 2025 with bilirubin stable around 2.5 mg/dL, but her pruritus is now debilitating. We request approval for compassionate use of linerixibat with close monitoring.
- Principal Investigator: Cynthia Levy
- Study Phase: TBD
- Enrollment Status: Closed
-
An expanded-access program for maralixibat in Patients with Progressive Familial Intrahepatic Cholestasis.34 yo female, 64.5Kg, with large duct primary sclerosing cholangitis and Crohn’s disease status post total proctocolectomy + J pouch + IPAA, suffering from intractable itching. The itching is disabling. She failed every available pharmacological agent for treatment of cholestatic pruritus. She has had multiple ERCPs with only temporary improvement. Liver transplantation was considered but she does not have cirrhosis and her MELD score is too low.She has tried: cholestyramine, hydroxyzine and butorphanol spray with minimal improvement. Not a good candidate for rifampin due to significant elevation of liver chemistries, and not a candidate for sertraline due to prior suicidal ideation.Patient does not quality for ongoing clinical trials for pruritus due to 1) history of colon surgery and 2) elevated bilirubin Labs 7/2023 with TB 3.1 mg/dL, ALP 751, AST 205, ALT 272. This is her baseline and she meets exclusion criteria for trials.
- Principal Investigator: Cynthia Levy
- Study Phase: N/A
- Enrollment Status: Closed
-
This is a phase II, proof-of-concept, randomised study to evaluate the safety and efficacy of elafibranor 80 mg/day and 120 mg/day compared with placebo in adult participants with PSC. Sixty participants with PSC will be enrolled in the study. Participants will be stratified based on baseline ursodeoxycholic acid (UDCA) status (ongoing UDCA treatment versus no ongoing UDCA treatment) and randomised in a 1:1:1 allocation ratio to elafibranor 80 mg/day, elafibranor 120 mg/day or placebo over the 12-week DBP. The DBP of the study will end when the last participant enrolled has completed 12 weeks of treatment. Thereafter, all participants will receive elafibranor 120 mg once daily in a 96-week OLE period. If at the time of the Week 12 primary analysis, it is determined by the Ipsen Data Review and Decision Committee (DRDC) that the 80 mg dose demonstrates a preferable safety and/or efficacy profile, participants already in the OLE period will undergo dose reduction to 80 mg once daily.
- Principal Investigator: Cynthia Levy
- Study Phase: TBD
- Enrollment Status: Closed
-
The purpose of this study is to find out the safety and tolerability (the degree to which side effects affect a participants willingness to continue taking study drug) of the study drug EP547 in patients with itch associated with cholestatic liver disease and to determine the amount of EP547 in the blood after dosing. EP547 is an experimental drug that is not approved by any Health Authorities including United States Food and Drug Administration (FDA) for the treatment of itch associated with liver disease. EP547 is not approved for the treatment of any other conditions.
- Principal Investigator: Cynthia Levy
- Study Phase: TBD
- Enrollment Status: Closed
-
The Main Part of this study will be a randomized, placebo-controlled, double-blind, parallel-group, multicenter, adaptive Phase 2b/3 trial assessing oral setanaxib administered as an add-on therapy in patients with early PBC, elevated liver stiffness, and intolerance or inadequate response to UDCA. The safety and efficacy of 1200 mg/day and 1600 mg/day setanaxib will be assessed against matching placebo over up to 52 weeks of treatment. The safety and efficacy of setanaxib will be further assessed during a 52-week Extension Phase. It is planned to enroll up to a total of 318 patients at approximately 150 to 200 investigational centers in North America, Europe, Israel, Australia, and New Zealand
- Principal Investigator: Cynthia Levy
- Study Phase: Phase II
- Enrollment Status: Closed
-
A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Closed
-
The study involves research on bitopertin, which is the experimental drug in this study. The purpose of the study is to evaluate the safety and efficacy of bitopertin in the treatment of patients with EPP.EPP is an inherited metabolic disorder that causes the build-up of substances called protoporphyrins in the red blood cells that causes painful reactions when exposed to light and can cause liver disease.
- Principal Investigator: Cynthia Levy
- Study Phase: TBD
- Enrollment Status: Closed
-
The study is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, operationally seamless, adaptive design clinical study that will be conducted as follows:1) screening, 2) study treatment period, and 3) optional OLE. The study treatment period comprises the single-blind, placebo run-in and double-blind treatment periods and will last a total of 28 weeks. The study (screening plus the study treatment period) will be conducted in 2 parts—Part 1: Interim Analysis and Dose Selection and Part 2: Confirmatory Stage.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase II
- Enrollment Status: Closed
-
This is a Phase 3, multicenter, double-blind, placebo-controlled, parallel-group study of bitopertin to evaluate the efficacy, safety, and tolerability in participants with EPP or XLP.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Open
-
This is a Phase 3, international, multicenter, open-label, long-term extension study to further evaluate safety and tolerability of MT-7117 administered once daily in subjects with EPP/XLP who previously participated in either study MT-7117-G01 or MT-7117-A-302. Both studies are Phase 3, randomized, double-blind, placebo-controlled studies to evaluate efficacy, safety, and tolerability in adults and adolescents with EPP or XLP. MT-7117-G01 is a completed study and MT-7117-A-302 is currently ongoing. This open-label extension study (MT-7117-A-301) offers the opportunity for patients who completed either study MT-7117-G01 (including the doubleblind extension period) or study MT-7117-A-302 (including the open-label extension period), to continue to be treated with MT-7117 up to 286 weeks (66 months).
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Open
-
This is a prospective, multicenter, open-label, extension study to evaluate the safety and efficacy of Saroglitazar Magnesium in participants with Primary Biliary Cholangitis.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Not Accepting
-
This is a phase III, randomised, double-blind, multicentre, parallel-group study to evaluate the safety and efficacy of elafibranor 80 mg compared with placebo in male and female participants aged 18 years or more with PBC. Assuming a screen failure rate of 50%, approximately 900 prospective participants will be screened in order to enrol 450 eligible participants with PBC. Participants will be randomised in a 2:1 allocation ratio to two parallel treatment arms: elafibranor 80 mg/day or placebo. Assignment to study intervention will be stratified into three strata: participants with no cirrhosis at baseline, participants with cirrhosis at baseline who are not Child Pugh B, and participants with cirrhosis who are Child Pugh B. When applicable, participants may continue to receive stable maintenance doses of UDCA throughout study participation. Participants musttake the study intervention by mouth once daily before breakfast with a glass of water at approximately the same time each morning.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Open
-
This is a Phase 3, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of MT-7117 in adults and adolescents with EPP or XLP. The study consists of 4 periods: a 4-week screening period, a 16-week double-blind placebo-controlled treatment period, a 36-week open-label extension period, and a 6-week safety follow-up period.The total study duration is up to 62 weeks.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Closed
-
This is a Phase 2, randomized, placebo-controlled, parallel group, multicenter, 12-week trial with a 52-week extension to evaluate the efficacy and safety of two doses of K-808 in subjects with PBC with inadequate response to UDCA and/or OCA treatment. Subjects taking OCA (alone or in combination with UDCA) are not eligible to participate in the 52-week Extension. For these subjects, study drug treatment will end with the end of the 12-week treatment period.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase II
- Enrollment Status: Closed
-
This is a multicenter evaluation of seladelpar, administered as a once-daily oral capsule, in a randomized, double-blind, placebo-controlled, parallel-group study in subjects with PBC. This fixed-duration study (156 weeks) will randomize approximately 192 subjects across approximately 150 sites worldwide. The population to be studied is subjects with PBC and compensated cirrhosis restricted to CP-A or CP-B.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III/IV
- Enrollment Status: Open
-
This open-label, multi-center study will evaluate the long-term safety, tolerability, and efficacy of bitopertin in participants with EPP. The study will be conducted at approximately 12 centers globally.
- Principal Investigator: Cynthia Levy
- Study Phase: Other
- Enrollment Status: Open
-
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study of seladelpar in patients with PBC and ALP values greater than ULN but less than 1.67ULN with either concomitant UDCA treatment or an intolerance to UDCA. Approximately 75 subjects will be randomized in a 2:1 ratio (seladelpar:placebo) across approximately 26 sites.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Closed
-
A Multicenter, Randomized, Double-blind, Placebo Controlled, Phase 2b/3 Study to Evaluate the Efficacy and Safety of Saroglitazar Magnesium in Subjects With Primary Biliary Cholangitis
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
A Phase 2a, Double-Blind, Randomized, Active Controlled, Parallel Group Study Evaluating the Efficacy, Safety, and Tolerability of Bezafibrate Administered in Combination With Obeticholic Acid in Subjects With Primary Biliary Cholangitis
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2
- Enrollment Status: Closed
-
This will be a Phase 2, multicenter, double-blind, randomized, placebo-controlled study to assess the safety and efficacy of LB-P8 in adult patients with PSC. The study comprises 2 parts.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase II
- Enrollment Status: Closed
-
ASSURE: An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
RESPONSE: A Placebo-controlled, Randomized, Phase 3 Study to Evaluate the Efficacy and Safety of Seladelpar in Patients With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Volixibat in the Treatment of Cholestatic Pruritus in Patients With Primary Sclerosing Cholangitis
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2
- Enrollment Status: Not Accepting
-
A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Randomized, Double-blind, Dose-ranging, Placebo-controlled, Phase 2a Evaluation of the Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Participants With Primary Sclerosing Cholangitis (PSC) and Suspected Liver Fibrosis (INTEGRIS-PSC)
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2
- Enrollment Status: Closed
-
Evaluation of Efficacy, Safety and Tolerability of NGM282 (Aldafermin) in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (ALPINE 4)
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2
- Enrollment Status: Closed
-
Long-term Safety and Tolerability Study of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Not Accepting
-
A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate the Safety and Efficacy of Oral CR845 in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2
- Enrollment Status: Closed
-
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, and Efficacy of Cilofexor in Non-Cirrhotic Subjects With Primary Sclerosing Cholangitis
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 3
- Enrollment Status: Closed
-
A Resource of Blood and Other Biospecimens of Patients With Cholestatic Liver Disease and Unaffected Individuals
- Principal Investigator: Cynthia Levy
- Study Phase: N/A
- Enrollment Status: Open
-
A Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of VAY736 in Autoimmune Hepatitis
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2/Phase 3
- Enrollment Status: Closed
-
This is a 5-year, longitudinal, observational study of patients with NAFLD or NASH designed to specifically address important clinical questions that remain incompletely answered from registration trials. In addition to the study database, a bio specimen repository will also be included so that translational studies of genomics and biomarkers of response may be performed.Patient management will follow each site’s local standard of care and no specific treatments, clinical assessments, and or laboratory tests will be dictated by enrollment in TARGET-NASH. Enrolled patients will consent to the collection of three years of retrospective, redacted medical records including clinic notes, laboratory data, all prior imaging reports, radiographic and other diagnostic procedures such as cardiovascular examinations, and all prior liver biopsy reports. If available, pathology slides greater than 3 years old may be requested. Patients will then be followed in the prospective cohort for approximately 5 years. During this prospective follow-up, all medical records including but not limited to records of hospitalization, laboratory reports, clinic notes, telephone contact reports, medication lists, biopsy results, and imaging results will be collected. Patients will also be asked to provide an annual blood sample and complete patient reported outcome (PRO) surveys. Liver biopsy slides will be digitally preserved. TARGET-NASH will obtain the most recent biopsy prior to enrollment and any subsequent biopsy slides post enrollment for digital scanning.To avoid selection bias, sites enrolling patients will make every effort to offer enrollment to all patients with NAFLD or NASH meeting enrollment criteria beginning from the time of IRB approval at their respective site. Consecutive enrollment is preferred to accurately characterize treatment response and outcomes. While enrollment will be sequential, certain patient populations may be enriched in order to support the goals of the registry and ensure adequate representation of patients with NASH versus NAFLD, and within the NASH population, patients with definite versus probable diagnoses.Patients will be screened and enrolled at a regularly scheduled clinic visit. For patients who provide consent and meet all inclusion/exclusion criteria, all redacted medical records (described above) will be submitted by the clinical center. An optional blood sample for DNA and serum will be collected. This sample will be collected during regular clinical blood work if possible, otherwise it will be collected by the study staff after consent has been obtained.Following the Screening/Enrollment visit, the clinical center will submit the patient’s redacted medical records that accumulated since the prior study visit at 6-month intervals for up to 5 years. Patients will be asked to complete PRO surveys at regular intervals during this follow-up period as well as provide an annual blood sample.
- Principal Investigator: Cynthia Levy
- Study Phase: N/A
- Enrollment Status: Closed
-
PrimaryTo assess the effect of OCA compared to placebo, in conjunction with established local standard of care, on clinical outcomes in subjects with primary biliary cirrhosis (PBC) as measured by time to first occurrence of any of the following adjudicated events, derived as a composite event endpoint:• Death (all-cause)• Liver transplant• Model of end stage liver disease (MELD) score ≥15• Hospitalization (as defined by a stay of 24 hours or greater) for new onset or recurrence of:− Variceal bleed− Encephalopathy (as defined by a West Haven score of ≥2)− Spontaneous bacterial peritonitis (confirmed by diagnostic paracentesis)• Uncontrolled ascites (diuretic resistant ascites requiring therapeutic paracentesis at a frequency of at least twice in a month)• Hepatocellular carcinoma confirmed by 2 complimentary imaging modalitiesSecondaryTo assess the effect of OCA compared to placebo on time to first occurrence of each individual component of the primary endpoint as listed above and also to include liver-related death.To assess the effect of OCA compared to placebo on disease progression via the following:• Liver biochemistry• Markers of inflammation and fibrosisTo assess the effect of OCA compared to historical controls on liver-related clinical outcomes.To assess the pharmacokinetics of OCA and its conjugates in a subset of subjects.To assess health outcomes and pharmacoeconomics including cost-effectiveness, resource utilization, and quality of life measures in subjects treated with OCA compared to placebo.To assess the safety and tolerability in subjects treated with OCA compared to placebo.
- Principal Investigator: Cynthia Levy
- Study Phase: Phase III
- Enrollment Status: Closed
-
A Randomized, Placebo-controlled Pilot Study of Sulfasalazine for the Treatment of Primary Sclerosing Cholangitis (PSC)
- Principal Investigator: Cynthia Levy
- Study Phase: Phase 2
- Enrollment Status: Closed
